Use of beta-glucans against biological warfare weapons and pathogens including anthrax
AssigneeBiopolymer Engineering, Inc.
InventorGary R. Ostroff
Life of this patent
Estimating the term…
Loading patent…
AssigneeBiopolymer Engineering, Inc.
InventorGary R. Ostroff
Estimating the term…
The present invention provides a means to broadly protect the military and the public from injury from biological warfare weapons, particularly infective agents such as anthrax. Beta (1,3)-glucans, particularly whole glucan particles, PGG-Glucan, and microparticulate glucan, provide general immune enhancement, thereby increasing the body's ability to defend against a wide variety of biological threats. Beta (1,3)-glucans have been shown to increase the resistance to infection by anthrax and other infectious organisms when administered before and after infection. The anti-infective mechanism of β(1,3)-glucan appears to involve stimulation of the innate immune system through increased cytokine release and CR3 receptor activation. Beta (1,3)-glucan is pharmaceutically stable, relatively compact, and can also be used without significant side effects. Beta (1,3)-glucan can also enhance the effectiveness of other medical countermeasures such as antibiotics, vaccines, and immune antibodies.
A method of treating or preventing pathogenesis of infection in humans or animals by one or more infectious agents comprising administering a prophylactically or therapeutically effective amount of β(1,3)-Glucan to the human or animal.
A method of preventing injury from biological warfare agents in humans or animals by administering a prophylactically or therapeutically effective amount of β(1,3)-Glucan.
A method of preventing injury from biological warfare agents in humans or animals comprising administering a prophylactically or therapeutically effective amount of a synergistic combination of β(1,3)-Glucan and antibiotic to the human or animal.
A method of synergistically preventing injury from biological warfare agents in humans or animals comprising administering a prophylactically or therapeutically effective amount of β(1,3)-Glucan subsequent to vaccination against said biological warfare agents to the human or animal.
A method of synergistically preventing injury from biological warfare agents in humans or animals by administering a prophylactically or therapeutically effective amount of β(1,3)-Glucan subsequent to treatment with immune sera or monoclonal antibody against said biological warfare agents.
Dependencies are inferred from the claim text.